Cargando…

In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy

BACKGROUND: In hypertrophic cardiomyopathy (HCM), autopsy studies revealed both increased focal and diffuse deposition of collagen fibers. Late gadolinium enhancement imaging (LGE) detects focal fibrosis, but is unable to depict interstitial fibrosis. We hypothesized that with T1 mapping, which is e...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouwer, Wessel P, Baars, Emma N, Germans, Tjeerd, de Boer, Karin, Beek, Aernout M, van der Velden, Jolanda, van Rossum, Albert C, Hofman, Mark BM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026831/
https://www.ncbi.nlm.nih.gov/pubmed/24766828
http://dx.doi.org/10.1186/1532-429X-16-28
_version_ 1782316906962747392
author Brouwer, Wessel P
Baars, Emma N
Germans, Tjeerd
de Boer, Karin
Beek, Aernout M
van der Velden, Jolanda
van Rossum, Albert C
Hofman, Mark BM
author_facet Brouwer, Wessel P
Baars, Emma N
Germans, Tjeerd
de Boer, Karin
Beek, Aernout M
van der Velden, Jolanda
van Rossum, Albert C
Hofman, Mark BM
author_sort Brouwer, Wessel P
collection PubMed
description BACKGROUND: In hypertrophic cardiomyopathy (HCM), autopsy studies revealed both increased focal and diffuse deposition of collagen fibers. Late gadolinium enhancement imaging (LGE) detects focal fibrosis, but is unable to depict interstitial fibrosis. We hypothesized that with T1 mapping, which is employed to determine the myocardial extracellular volume fraction (ECV), can detect diffuse interstitial fibrosis in HCM patients. METHODS: T1 mapping with a modified Look-Locker Inversion Recovery (MOLLI) pulse sequence was used to calculate ECV in manifest HCM (n = 16) patients and in healthy controls (n = 14). ECV was determined in areas where focal fibrosis was excluded with LGE. RESULTS: The total group of HCM patients showed no significant changes in mean ECV values with respect to controls (0.26 ± 0.03 vs 0.26 ± 0.02, p = 0.83). Besides, ECV in LGE positive HCM patients was comparable with LGE negative HCM patients (0.27 ± 0.03 vs 0.25 ± 0.03, p = 0.12). CONCLUSIONS: This study showed that HCM patients have a similar ECV (e.g. interstitial fibrosis) in myocardium without LGE as healthy controls. Therefore, the additional clinical value of T1 mapping in HCM seems limited, but future larger studies are needed to establish the clinical and prognostic potential of this new technique within HCM.
format Online
Article
Text
id pubmed-4026831
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40268312014-05-21 In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy Brouwer, Wessel P Baars, Emma N Germans, Tjeerd de Boer, Karin Beek, Aernout M van der Velden, Jolanda van Rossum, Albert C Hofman, Mark BM J Cardiovasc Magn Reson Research BACKGROUND: In hypertrophic cardiomyopathy (HCM), autopsy studies revealed both increased focal and diffuse deposition of collagen fibers. Late gadolinium enhancement imaging (LGE) detects focal fibrosis, but is unable to depict interstitial fibrosis. We hypothesized that with T1 mapping, which is employed to determine the myocardial extracellular volume fraction (ECV), can detect diffuse interstitial fibrosis in HCM patients. METHODS: T1 mapping with a modified Look-Locker Inversion Recovery (MOLLI) pulse sequence was used to calculate ECV in manifest HCM (n = 16) patients and in healthy controls (n = 14). ECV was determined in areas where focal fibrosis was excluded with LGE. RESULTS: The total group of HCM patients showed no significant changes in mean ECV values with respect to controls (0.26 ± 0.03 vs 0.26 ± 0.02, p = 0.83). Besides, ECV in LGE positive HCM patients was comparable with LGE negative HCM patients (0.27 ± 0.03 vs 0.25 ± 0.03, p = 0.12). CONCLUSIONS: This study showed that HCM patients have a similar ECV (e.g. interstitial fibrosis) in myocardium without LGE as healthy controls. Therefore, the additional clinical value of T1 mapping in HCM seems limited, but future larger studies are needed to establish the clinical and prognostic potential of this new technique within HCM. BioMed Central 2014-04-25 /pmc/articles/PMC4026831/ /pubmed/24766828 http://dx.doi.org/10.1186/1532-429X-16-28 Text en Copyright © 2014 Brouwer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research
Brouwer, Wessel P
Baars, Emma N
Germans, Tjeerd
de Boer, Karin
Beek, Aernout M
van der Velden, Jolanda
van Rossum, Albert C
Hofman, Mark BM
In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
title In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
title_full In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
title_fullStr In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
title_full_unstemmed In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
title_short In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
title_sort in-vivo t1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026831/
https://www.ncbi.nlm.nih.gov/pubmed/24766828
http://dx.doi.org/10.1186/1532-429X-16-28
work_keys_str_mv AT brouwerwesselp invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy
AT baarsemman invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy
AT germanstjeerd invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy
AT deboerkarin invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy
AT beekaernoutm invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy
AT vanderveldenjolanda invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy
AT vanrossumalbertc invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy
AT hofmanmarkbm invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy